ClinicalTrials.gg

Program

Akt Inhibitor NTQ1062

Also written as “NTQ1062+Fulvestrant”, “NTQ1062” and “NTQ1062 with Fulvestrant”.

In Sino Biopharmaceutical’s pipeline, AKT抑制剂. Its studies are mostly in Breast Neoplasms, led by Sino Biopharmaceutical.

Furthest: phase 3, since Jan 16, 20263 company-led studies, 2 open or runningNext primary completion: Aug 31, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical32 open or runningphase 3since Jan 16, 2026Nov 23, 2023Aug 31, 2028phase 3 · NCT07393321
  • Named in Sino Biopharmaceutical’s own pipeline as NTQ1062, phase 3, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 23, 2023First studies: 2 phase 1 studiesFirst studyNCT06172309, NCT06172322
  2. Jan 16, 2026Phase 3 study in Breast NeoplasmsPhase 3 reachedNCT07393321 · 210 planned

Ahead

  1. Aug 31, 2028Primary completion: phase 3 study in Breast NeoplasmsNCT07393321

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07393321Breast Neoplasms3Not yet recruitingAug 31, 2028210
NCT06172322HR Positive/HER-2 Negative Breast Cancer · China1RecruitingApr 202542
NCT06172309Advanced Solid Tumors · China1CompletedApr 20, 202432

How it is read

Names in the registry

  • “NTQ1062+Fulvestrant”, 1 entry
  • “NTQ1062”, 1 entry
  • “NTQ1062 with Fulvestrant”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.